Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

Overview of attention for article published in Annals of the Rheumatic Diseases, January 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#39 of 7,457)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 45 news stories from 40 outlets.

Classified in: Health Subject: TRI BIMZELX® (bimekizumab) is the first and only treatment approved by Health Canada for…

BIMZELX® (bimekizumab) is the first and only treatment approved by Health Canada for eligible patients with active psoriatic…

UCB Receives New European Commission Approvals for BIMZELX[®]▼(bimekizumab) for the Treatment of Psoriatic Arthritis and Axial…

Bimekizumab is the first and only IL-17A and IL-17F inhibitor approved in the European Union for active psoriatic arthritis (PsA…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 41 additional news stories.